Monocyte subsets and monocyte-related chemokines in Takayasu arteritis

Mariana Freitas de Aguiar1, Heron Torquato2,3, Bruno Ramos Salu4

  • 1Rheumatology Division, Department of Medicine, Universidade Federal de São Paulo-Escola Paulista de Medicina, Rua dos Otonis, 863, São Paulo, SP, 04025-002, Brazil.

Scientific Reports
|February 6, 2023
PubMed

Insights

Takayasu arteritis (TAK) is linked to changes in monocyte subsets, with higher intermediate monocytes observed in patients. C-C chemokine ligand 22 (CCL22) shows the strongest association with active TAK disease.

Area of Science:

  • Immunology
  • Rheumatology
  • Vascular Biology

Background:

  • The pathogenesis of Takayasu arteritis (TAK), a form of large vessel vasculitis, remains poorly understood.
  • Previous research has not investigated the role of monocytes or related chemokines in TAK.
  • Monocytes are key immune cells involved in inflammation and vascular damage.

Purpose of the Study:

  • To evaluate monocyte subsets and monocyte-related chemokines in the peripheral blood of TAK patients compared to healthy controls (HC).
  • To identify potential biomarkers associated with active TAK disease and treatment response.

Main Methods:

  • Peripheral blood samples were collected from 32 TAK patients and 30 HC.
  • Monocyte subsets (classical, intermediate, non-classical) were identified using flow cytometry.
  • Serum levels of chemokines including CCL2, CCL3, CCL4, CCL5, CCL7, CXCL10, and CX3CL1 were measured.

Main Results:

  • TAK patients exhibited higher intermediate monocyte counts compared to HC.
  • Active disease in TAK was associated with increased classical and intermediate monocyte subsets.
  • CCL22 levels were significantly higher in active TAK compared to remission, indicating a strong association with disease activity.
  • Prednisone treatment reduced non-classical monocyte percentages, while glucocorticoids lowered CXCL10 levels.

Conclusions:

  • Takayasu arteritis is characterized by distinct alterations in peripheral blood monocyte subsets.
  • CCL22 emerges as a promising chemokine biomarker for active Takayasu arteritis.
  • These findings contribute to a better understanding of TAK pathogenesis and may guide future diagnostic and therapeutic strategies.